The lung tissue contains various hemostatic system elements, which can be released from the lungs, both under physiological and pathological conditions. The COVID-19 pandemic has led to an increase in the number of patients with acute respiratory distress syndrome (ARDS) in intensive care units worldwide. When the lungs are damaged, coagulation disorders are mediated by tissue factor (TF) - factor VIIa (F VIIa), and inhibition of this pathway completely eliminates intrapulmonary fibrin deposition. A tissue factor pathway inhibitor TFPI also contributes to pulmonary coagulationdisturbance in ARDS. Pulmonary coagulationdisturbance caused by pneumonia can worsen the damage to the lungs and thus contribute to the progression of the disease. Cytokines are the main linking factors between inflammation and changes in blood clotting and fibrinolysis. The sources of proinflammatory cytokines in the lungs are probably alveolar macrophages. The activation of alveolar macrophages occurs through the nuclear factor kappa-bi (NF-κB), which controls thetranscription of the expression of immune response genes, cell apoptosis, which leads to the development of inflammation and autoimmune diseases as a result of direct stimulation of TF activation. Conversely,coagulation itself can affect bronchoalveolar inflammation. Coagulation leads to the formation of proteases that interact with specific cellular receptors, activating intracellular signaling pathways. The use of anticoagulant therapy, which also has an anti-inflammatory effect, perhaps one of the therapeutic targets for coronavirus infection.The difficulty here is that it seems appropriate to study anticoagulant interventions’ influence on clinically significant cardio-respiratory parameters.

Lysosomal storage disorders (LSDs) are genetically and clinically heterogeneous conditions in which delayed recognition may permit irreversible multisystem injury. Flow-injection analysis tandem mass spectrometry (FIA-MS/MS) of dried blood spots (DBS) provides a practical first-tier approach for multiplex lysosomal enzyme measurement. We performed a retrospective descriptive analysis of 14,989 valid unique pediatric DBS sample records from 13 geographic categories in Uzbekistan during 2025 after exclusion of technical/non-interpretable entries and duplicate plate identifiers. Of these, 386 samples were laboratory-positive (2.58%). Pompe disease was the most frequent category (141/386, 36.5%), followed by Krabbe disease (105/386, 27.2%), Gaucher disease (76/386, 19.7%), acid sphingomyelinase deficiency/Niemann-Pick disease type A/B (48/386, 12.4%), Fabry disease (10/386, 2.6%), and mucopolysaccharidosis type I (MPS I) based on reduced α-L-iduronidase (IDUA) activity (6/386, 1.6%). Regional sample denominators were available for all 13 geographic categories; the highest laboratory-positive proportion was observed in Surkhandarya (42/570; 7.37%), followed by Samarkand (87/2604; 3.34%), Kashkadarya (70/2152; 3.25%), and Khorezm (44/1366; 3.22%). Among the laboratory-positive samples, median first-tier activities corresponded to 80.5% for acid β-glucocerebrosidase (ABG), 79.6% for acid sphingomyelinase (ASM), 81.6% for acid α-glucosidase (GAA), 68.3% for galactocerebrosidase (GALC), 53.5% for α-galactosidase A (GLA), and 15.5% for IDUA relative to the respective decision limits. These results represent first-tier laboratory-positive signals in a selectively tested sample cohort rather than confirmed diagnoses or population incidence/prevalence. Systematic biochemical and molecular confirmation, patient-level linkage, and analytical batch review are required for definitive interpretation.

Lysosomal storage disorders (LSDs) are genetically and clinically heterogeneous conditions in which delayed recognition may permit irreversible multisystem injury. Flow-injection analysis tandem mass spectrometry (FIA-MS/MS) of dried blood spots provides a practical first-tier approach for multiplex lysosomal enzyme measurement. We performed a retrospective descriptive analysis of 14,989 valid unique pediatric DBS sample records from 13 geographic categories in Uzbekistan during 2025 after exclusion of technical/non-interpretable entries and duplicate plate identifiers. Of these, 386 samples were laboratory-positive (2.58%). Pompe disease was the most frequent category (141/386, 36.5%), followed by Krabbe disease (105/386, 27.2%), Gaucher disease (76/386, 19.7%), acid sphingomyelinase deficiency/Niemann-Pick disease type A/B (48/386, 12.4%), Fabry disease (10/386, 2.6%), and MPS I based on reduced IDUA activity (6/386, 1.6%). Regional sample denominators were available for all 13 geographic categories; the highest laboratory-positive proportion was observed in Surkhandarya (42/570; 7.37%), followed by Samarkand (87/2,604; 3.34%), Kashkadarya (70/2,152; 3.25%), and Khorezm (44/1,366; 3.22%). Median first-tier activities corresponded to 80.5% (ABG), 79.6% (ASM), 81.6% (GAA), 68.3% (GALC), 53.5% (GLA), and 15.5% (IDUA) of the respective decision limits. These results represent first-tier laboratory-positive signals in a selectively tested sample cohort rather than confirmed diagnoses or population incidence/prevalence. Systematic biochemical and molecular confirmation, patient-level linkage, and analytical batch review are required for definitive interpretation.